eotaxin-3 CRISPR/Cas9 KO Plasmid (h): sc-405762
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- eotaxin-3 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the eotaxin-3 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: eotaxin-3 Antibody (500-M32): sc-65349
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
eotaxin-3 CRISPR/Cas9 KO Plasmid (h) | sc-405762 | 20 µg | $397.00 |
Overview
CCL26 encodes eotaxin-3, a CC chemokine that binds CCR3 to direct chemotaxis and activation of eosinophils, basophils, and Th2-polarized immune cells. Its expression is commonly induced in epithelial and stromal compartments by IL-4/IL-13 signaling through the JAK–STAT6 axis, linking it to type 2 inflammatory programs and leukocyte trafficking. Eotaxin-3 contributes to regulation of tissue inflammation, barrier-associated immune responses, and cytokine–chemokine network amplification. Altered CCL26 regulation and elevated eotaxin-3 have been reported in allergic and eosinophil-associated inflammatory conditions, supporting its utility as a mechanistic node in inflammation research.
eotaxin-3 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the CCL26 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the CCL26 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the CCL26 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish eotaxin-3 protein expression.
This CRISPR knockout system enables efficient generation of CCL26-deficient cell models for investigation of eotaxin-3 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting CCL26 exon(s) critical for eotaxin-3 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple CCL26 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by eotaxin-3 CRISPR/Cas9 KO Plasmid (h) and eotaxin-3 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the CCL26 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by eotaxin-3 HDR Plasmid (h) and eotaxin-3 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by CCL26 homology arms to support homology-directed repair at defined CCL26 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.